Abstract
There has been a real interest recently in developing once-daily β2-adrenoceptor agonists (ultra-long-acting β2-adrenoceptor agonists [ultra-LABAs]) for treating asthma and chronic obstructive pulmonary disease (COPD) in an attempt to simplify their management, although an increasing amount of convincing data show an association of LABAs with a rise in asthma-related deaths and life-threatening experiences. This paper reviews the effects of different ultra-LABAs that are at varying stages of development. Arformoterol, carmoterol, indacaterol and GSK-159797 are ultra-LABAs that are likely to be introduced into the market before 2010. It is plausible that once-daily dose administration of an LABA will lead to increased convenience for patients, which may also lead to enhancement of adherence, and may have advantages leading to improved overall clinical outcomes in patients with asthma and COPD.
Similar content being viewed by others
Notes
The use of tradenames is for identification purposes only and does not imply endorsement.
References
Waldeck B. Some pharmacodynamic aspects on long-acting β-adrenoceptor agonists. Gen Pharmacol 1996; 27: 575–80
Novel long-acting β2 agonists; Glaxo Wellcome plc: WO02070490 & WO02076933. Current Opin Ther Patents 2003; 13: 273–7
Global Initiative for Asthma. GINA workshop report: global strategy for asthma management and prevention [online]. Available from URL: http://www.ginasthma.com [Accessed 2006 Sep 26]
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2005 update [online]. Available from URL: www.goldcopd.com [Accessed 2006 Sep 27]
Cazzola M, Matera MG, Lötvall J. Ultra long-acting β2 agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005; 14: 775–83
Campbell LM. Once-daily inhaled corticosteroids in mild to moderate asthma: improving acceptance of treatment. Drugs 1999; 58 Suppl. 4: 25–33
Donohue JF, Fromer L. Long-acting β-agonists role in asthma management. J Fam Pract 2006; Suppl.: 1–6
Castle W, Fuller RW, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306: 1034–7
Spitzer WO, Suissa S, Ernst P, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326: 501–6
Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15–26
Martinez FD. Safety of long-acting β-agonists: an urgent need to clear the air. N Engl J Med 2005, 2639
FDA Public Health Advisory. Serevent Diskus (salmeterol xinafoate inhalation powder), Advair Diskus (fluticasone propionate & salmeterol inhalation powder), Foradil Aerolizer (formoterol fumarate inhalation powder) [online]. Available from URL: www.fda.gov/cder/driig/advisory/LABA.htm [Accessed 2006 May 28]
Donohue JF. Therapeutic responses in asthma and COPD: bronchodilators. Chest 2004; 126 (2 Suppl.): 125–37S
Yates DH, Sussman HS, Shaw MJ, et al. Regular formoterol treatment in mild asthma: effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med 1995; 152: 1170–4
Cheung D, Timmers MC, Zwinderman AH, et al. Long-term effects of long-acting beta-2 adrenoceptor agonist salmeterol on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327: 1198–203
Ramage L, Lipworth BJ, Ingram CG, et al. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994; 88: 363–8
Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995; 346: 201–6
Newnham DM, McDevitt DG, Lipworth BJ. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med 1994; 97: 29–37
Tan S, Hall IP, Dewar J, et al. β2-Adrenoceptor polymorphism is associated with susceptibility to bronchodilator desensitization in moderately severe stable asthmatics. Lancet 1997; 350: 995–9
Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting β-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144: 904–12
Lipworth BJ, Hall IP, Tan S, et al. Effects of genetic polymorphism on ex vivo and in vivo function of β2-adrenoceptors in asthmatic patients. Chest 1999; 115: 324–8
Wechsler ME, Lehman E, Lazarus SC, et al. β-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173: 519–26
Page CP, Morley J. Contrasting properties of albuterol stereo-isomers. J Allergy Clin Immunol 1999; 104: S31–41
Ameredes BT, Calhoun WJ. Modulation of GM-CSF release by enantiomers of β-agonists in human airway smooth muscle. J Allergy Clin Immunol 2005; 116: 65–72
Waldeck B. β-Adrenoceptor agonists and asthma: 100 years of development. Eur J Pharmacol 2002; 445: 1–12
Arformoterol: (R,R)-eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, R,R-eformoterol, R,R-formoterol. Drugs R D 2004; 5: 25–7
Handley DA, Senanayake CH, Dutczak W, et al. Biological actions of formoterol isomers. Pulm Pharmacol Ther 2002; 15: 135–45
Vaickus L, Claus R. (R;R)-formoterol: rapid onset and 24h duration of response after a single dose [abstract]. Am J Respir Crit Care Med 2000; 161: A191
Lötvall J, Palmqvist M, Ankerst J, et al. The effect of formoterol over 24h in patients with asthma: the role of enantiomers. Pulm Pharmacol Ther 2005; 18: 109–13
Baumgartner RA, Mazzetti A, Claus R, et al. Crossover dose-ranging study of arformoterol in patients with COPD [abstract]. Proc Am Thorac Soc 2006; 3: A847
Hanrahan JP, Sahn SA, Busse WW, et al. Efficacy of nebulized arformoterol, a long-acting β2-adrenergic bronchodilator, in patients with COPD [abstract]. Eur Respir J 2006; 28: 215s
Hanrahan JP, Kerwin E, Cheng H, et al. Arformoterol in COPD: safety results from two pooled phase 3 trials [abstract]. Eur Respir J 2006; 28: 428s
Kikkawa H, Naito K, Ikezawa K. Tracheal relaxing effects and β2-selectivity of TA-2005, a newly developed bronchodilating agent, in isolated guinea-pig tissues. Jpn J Pharmacol 1991; 57: 175–85
Voss H-P, Donneil D, Bast A. Atypical molecular pharmacology of a new long-acting β2-adrenoceptor agonist, TA-2005. Eur J Pharmacol 1992; 227: 403–9
Standifer KM, Pitha J, Baker SP. Carbostyril-based β-adrenergic agonists: evidence for long lasting or apparent irreversible receptor binding and activation of adenylate cyclase activity in vitro. Naunyn-Schmiedeberg’s Arch Pharmacol 1989; 339: 129–37
Kikkawa H, Isogaya M, Nagao T, et al. The role of the seventh transmembrane region in high affinity binding of a β2-selective agonist TA-2005. Mol Pharmacol 1998; 53: 128–34
Voss HP, Shukrula S, Wu TS, et al. A functional β2 adrenoceptor-mediated chronotropic response in isolated guinea pig heart tissue: selectivity of the potent β2 adrenoceptor agonist TA 2005. J Pharmacol Exp Ther 1994; 271: 386–9
Kikkawa H, Kanno K, Ikezawa K. TA-2005, a novel, long-acting and selective β2-adrenocepter agonist: characterization of its in vivo bronchodilating action in guinea pigs and cats in comparison with other β2-agonists. Biol Pharm Bull 1994; 17: 1047–52
Voss H-P. Long-acting β2-adrenoceptor agonists in asthma: molecular pharmacological aspects. Thesis, VrijeUniversiteit: Amsterdam, 1994
Chiesi Farmaceutici S.p.A. Investigator’s brochure: CHF 4226. June 2004 (Data on file)
Kottakis I, Nandeuil A, Raptis H, et al. Comparison of the efficacy and safety of 5 different doses of the novel very long acting β2-agonist carmoterol [abstract]. Eur Respir J 2006; 28: 666s
Linberg SE, Heyman ER, Nandeuil MA, et al. Cardiac safety of the novel very long-acting beta2-agonist carmoterol following single rising doses in healthy volunteers [abstract]. Eur Respir J 2006; 28: 665s
Haeussermann S, Acerbi A, Brand P, et al. Lung deposition of carmoterol in healthy subjects, patients with asthma and patients with COPD [abstract]. Eur Respir J 2006; 28: 211s
Kottakis I, Nandeuil A, Helene Raptis H, et al. Efficacy of the novel very long-acting β2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma [abstract]. Eur Respir J 2006; 28: 665s
Nandeuil A, Kottakis I, Raptis H, et al. Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma [abstract]. Eur Respir J 2006; 28: 665s
Rossoni G, Manfredi B, Razzetti R, et al. Positive interaction of the novel β2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs. Pulm Pharmacol Ther. Epub 2006 Mar 11
Rossoni G, Manfredi B, Razzetti R, et al. Positive interaction of the β2-agonist CHF 4226.01 with budesonide in the control of bronchoconstriction induced by acetaldehyde in the guineapigs. Br J Pharmacol 2005; 144: 422–9
Currie GP. Indacaterol Novartis/SkyePharma. Curr Opin Investigat Drugs 2006; 7: 457–63
Battram C, Charlton SJ, Cuenoud B, et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-Diethylin-dan-2-ylamino)-l-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled β2 adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006; 317: 762–70
Lewis CA, Jordan L, Wyss D, et al. QAB149, a novel 24-hour. Proc Am Thorac Soc 2005; 2: A355
Naline E, Molimard M, Fairhurst R, et al. Duration and onset of action of QAB149, a novel 24-hour β2-agonist, on the isolated human bronchus [abstract]. Proc Am Thorac Soc 2005; 2: A356
Trifilieff A, Barnes PJ, Sturton RG. Pharmacological characterisation of indacaterol (QAB149), a novel once-daily inhaled β2-agonist, on small airways in human and rat lung slices [abstract]. Eur Respir J 2006; 28: 114s
Naline E, Molimard M, Fairhurst R, et al. Pharmacological characterization of QAB149, a novel 24-hour β2-agonist, on the isolated human bronchus [abstract]. Proc Am Thorac Soc 2005; 2: A356
Lewis CA, Jordan L, Farr DC, et al. Indacaterol: preclinical evidence for an improved safety profile vs LABAs [abstract]. Eur Respir J 2005; 26 Suppl. 49: 216s
Battram CH, Mok J, Lewis CA. Once-daily administration of QAB149 does not induce tachyphylaxis in vivo [abstract]. Proc Am Thorac Soc 2005; 2: A356
Beeh K-M, Schelfout V, Gronke L, et al. QAB149: the first once-daily β2-agonist with 24-hour bronchodilation [abstract]. Proc Am Thorac Soc 2005; 2: A356
Pearlman D, Greos L, LaForce C, et al. Indacaterol, a novel once-daily β2-agonist, provides full 24-hour bronchodilator efficacy in patients with persistent asthma [abstract]. Proc Am Thorac Soc 2006; 3: A79
LaForce C, Aisanov Z, Higgins M, et al. Indacaterol, a novel once-daily β2-agonist, demonstrates efficacy and safety in patients with persistent asthma: a 7-day, multiple-dose study [abstract]. Proc Am Thorac Soc 2006; 3: A79
Duvauchelle T, Elharrar B, Knight H, et al. Single-dose indacaterol, a novel once-daily β2-agonist, is well tolerated in patients with mild asthma [abstract]. Eur Respir J 2005; 26 Suppl. 49: 253s
Tarral A, Fauchoux N, Knight H, et al. Safety and tolerability of multiple-dose indacaterol, a novel once-daily β2-agonist, in patients with mild asthma [abstract]. Eur Respir J 2005; 26 Suppl. 49: 253s
Chuchalin AG, Tsoi A, Richter K, et al. Cardiovascular safety of indacaterol, a novel once-daily β2-agonist, in patients with asthma [abstract]. Eur Respir J 2005; 26 Suppl. 49: 253s
Aubier M, Duval X, Knight H, et al. Indacaterol, a novel once-daily β2-agonist is effective and well tolerated on multiple dosing in patients with mild-to-moderate COPD [abstract]. Eur Respir J 2005; 26 Suppl. 49: 287s
Rennard S, Bantje T, Higgins M, et al. Indacaterol, a novel once-daily β2-agonist, provides 24-hour bronchodilator efficacy in moderate-to-severe COPD [abstract]. Proc Am Thorac Soc 2006, A118
Kanniess F, Cameron R, Owen R, et al. Indacaterol, a novel once-daily β2-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with persistent asthma: a multiple-dose, dose-ranging study [abstract]. Eur Respir J 2005; 26 Suppl. 49: 253s
Pascoe S, Knowles LJ, Glasbrenner M, et al. Efficacy and safety of therapeutic and supratherapeutic doses of indacaterol compared to salmeterol and salbutamol, in mild-to-moderate asthma [abstract]. Eur Respir J 2006; 28: 207s
Novartis presents positive Phase III data on key compounds and highlights strong late-stage development pipeline [online]. Available from URL: http://hugin.info/134323/R/1012406/157718.pdf#search=%22NVA-237%20and%20indacaterol%22 [Accessed 2006 Sep 27]
Novartis and Schering-Plough collaboration to develop novel once-daily combination therapy for asthma and COPD [online]. Available from URL: www.medicalnewstoday.com/medicalnews.php?.newsid=50031 [Accessed 2006 Sep 27]
New long-acting β2-agonists. Theravance, Inc: WO2004011 416. Current Opin Ther Patents 2004; 14: 1385–8
Theravance announces results of phase 2 clinical study showing 24-hour bronchodilation with investigational medicine [online]. Available from URL: http://thera.client.shareholder.com/ReleaseDetail.cfm?.ReleaseID=167314 [Accessed 2006 Sep 27]
Hanania NA, Sharafkhaneh A, Barber R, et al. β-Agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med 2002; 165: 1353–8
Handley D. The asthma-like pharmacology and toxicology of the (S)-isomers of β-agonists. J Allergy Clin Immunol 1999; 104: S69–76
Acknowledgements
Professor Matera has received honoraria for consulting and/or financial support for attending meetings from Altana, AstraZeneca, Boehringer Ingelheim, GSK, Novartis and Pfizer. Professor Cazzola has received honoraria for speaking and consulting and/or financial support for attending meetings from Altana, AstraZeneca, Aventis, Boehringer Ingelheim, Chiesi Farmaceutici, Dey, GSK, Meda, Menarini Farmaceutici, Novartis, Pfizer, Sanovel and Valeas, and is a member of the speaker bureau of Novartis. No funding has been provided for this article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Matera, M.G., Cazzola, M. Ultra-Long-Acting β2-Adrenoceptor Agonists. Drugs 67, 503–515 (2007). https://doi.org/10.2165/00003495-200767040-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200767040-00002